Apellis Pharmaceuticals (APLS) Stock Statistics & Valuation Metrics

Apellis Pharmaceuticals has a market cap or net worth of $2.56B. The enterprise value is $2.57B.

Apellis Pharmaceuticals has 127,829,910 shares outstanding. The number of shares has decreased by -2.65% in one year.

Apellis Pharmaceuticals’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 6.04%.

The current PE Ratio of Apellis Pharmaceuticals is 141.4. Apellis Pharmaceuticals’s PEG ratio is -1.27.

In the last 12 months, Apellis Pharmaceuticals had revenue of 1.00B and earned 22.39M in profits. Earnings per share was 0.18.

In the last 12 months, operating cash flow was 45.33M and capital expenditures 0.00, giving a free cash flow of 45.33M billion.

Apellis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Apellis Pharmaceuticals upcoming earnings date is Apr 30, 2026, After Close (Confirmed).

Apellis Pharmaceuticals as a current ratio of 3.14, with Debt / Equity ratio of 131.38%

In the past 12 months, Apellis Pharmaceuticals has paid 1.72M in taxes.

Apellis Pharmaceuticals EV to EBITDA ratio is 45.49, with an EV/FCF ratio of 70.74.

Apellis Pharmaceuticals has $467.76M in cash and marketable securities with $486.31M in debt, giving a net cash position of -$18.55M billion.

Gross margin is 89.77%, with operating margin of 5.52%, and net profit margin of 2.23%.

The average price target for Apellis Pharmaceuticals is $31.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy